Importance Dapsone-induced hypersensitivity syndrome (DHS) is a life-threatening adverse drug reaction. Based on available epidemiologic studies, HLA genotypes may play an important role in DHS. Objective To assess the association betweenHLA-B*1301and dapsone-induced cutaneous adverse drug reactions (cADRs). Data Sources Human studies investigating associations betweenHLA-B*1301and dapsone-induced cADRs were systematically searched without language restriction from the inception of each database until September 12, 2017, in PubMed, the Human Genome Epidemiology Network), and the Cochrane Library. Combinations ofHLA genotypes, dapsone,and synonymous terms were used; reference lists were searched in selected articles. Study Selection Two reviewers identified studies investigating the associations betweenHLA-B*1301and dapsone-induced cADRs that reported sufficient data for calculating the frequency ofHLA-B*1301carriers among case and control patients, in which all patients received dapsone beforeHLA-B*1301screening. An initial search of the databases identified 391 articles, of which 3 studies (2 in Chinese populations and 1 in a Thai population) met the inclusion criteria. Data Extraction and Synthesis Overall odds ratios (ORs) with 95% CIs were calculated using a random-effects model to determine the association betweenHLA-B*1301and dapsone-induced cADRs. Subgroup analyses by type of cADR were also performed. PRISMA guidelines were used to abstract and assess data. Main Outcomes and Measures Primary outcomes were associations betweenHLA-B*1301and dapsone-induced cADRs in dapsone-tolerant controls. The outcomes are reported as overall OR. Statistical heterogeneity was assessed using theQstatistic andI2tests. Results From the 3 included studies, there were 111 unique patients with dapsone-induced cADRs (subsequently used in the meta-analysis), 1165 dapsone-tolerant patients, and 3026 healthy controls. The cases included 64 men and 49 women (2 patients were missing from the meta-analysis; 1 each from 2 of the 3 studies); mean age was 39.7 years. An association betweenHLA-B*1301and dapsone-induced cADRs was identified (summary OR, 43.0; 95% CI, 24.0-77.2). Subgroup analyses among types of cADRs produced similar findings in DHS (OR, 51.7; 95% CI, 16.9-158.5), dapsone-induced severe cADRs (Stevens-Johnson syndrome and toxic epidermal necrolysis [SJS/TEN] plus drug rash [adverse skin reaction to a drug] along with eosinophilia and systemic symptoms [DRESS]) (OR, 54.0; 95% Cl, 8.0-366.2), dapsone-induced SJS/TEN (OR, 40.5; 95% CI, 2.8-591.0), and dapsone-induced DRESS (OR, 60.8; 95% CI, 7.4-496.2). There was no heterogeneity (I2= 0%,P= .38). Conclusions and Relevance Associations betweenHLA-B*1301and dapsone-induced cADRs were found in dapsone-tolerant and healthy control groups. For patient safety, genetic screening forHLA-B*1301in Asian populations before dapsone therapy is warranted.